Effect of 4 years of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.
AMA1
Antibody to MSP-142
CSP
Seasonal malaria chemoprevention
Seropositivity
Journal
Malaria journal
ISSN: 1475-2875
Titre abrégé: Malar J
Pays: England
ID NLM: 101139802
Informations de publication
Date de publication:
07 Jan 2021
07 Jan 2021
Historique:
received:
08
09
2020
accepted:
10
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
10
7
2021
Statut:
epublish
Résumé
More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended in 2012 by WHO. This strategy is now implemented widely and protected more than 19 million children in 2018. It was previously reported that exposure to SMC reduced antibody levels to AMA1, MSP-1 In 2017, a cross-sectional survey was carried out 1 month after the last dose of SMC had been given to children aged 4-5 years randomly selected from areas where SMC had been given for 2 or 4 years during the malaria transmission season. A total of 461 children were enrolled, 242 children in areas where SMC had been implemented for 4 years and 219 children in areas where SMC had been implemented for 2 years. Antibody extracted from dry blood spots was used to measure IgG levels to the malaria antigens CSP, MSP-1 The prevalence of antibodies to MSP-1 In an area of high seasonal malaria transmission, children who had received SMC for 4 years did not had lower seropositivity or antibody levels to AMA1, MSP-1
Sections du résumé
BACKGROUND
BACKGROUND
More than 200 million people live in areas of highly seasonal malaria transmission where Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) and amodiaquine (AQ) was recommended in 2012 by WHO. This strategy is now implemented widely and protected more than 19 million children in 2018. It was previously reported that exposure to SMC reduced antibody levels to AMA1, MSP-1
METHODS
METHODS
In 2017, a cross-sectional survey was carried out 1 month after the last dose of SMC had been given to children aged 4-5 years randomly selected from areas where SMC had been given for 2 or 4 years during the malaria transmission season. A total of 461 children were enrolled, 242 children in areas where SMC had been implemented for 4 years and 219 children in areas where SMC had been implemented for 2 years. Antibody extracted from dry blood spots was used to measure IgG levels to the malaria antigens CSP, MSP-1
RESULTS
RESULTS
The prevalence of antibodies to MSP-1
CONCLUSION
CONCLUSIONS
In an area of high seasonal malaria transmission, children who had received SMC for 4 years did not had lower seropositivity or antibody levels to AMA1, MSP-1
Identifiants
pubmed: 33413417
doi: 10.1186/s12936-020-03542-9
pii: 10.1186/s12936-020-03542-9
pmc: PMC7788529
doi:
Substances chimiques
Antibodies, Protozoan
0
Antigens, Protozoan
0
Antimalarials
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
23Références
PLoS Med. 2011 Feb 01;8(2):e1000408
pubmed: 21304925
PLoS Clin Trials. 2007;2(4):e12
pubmed: 17415408
PLoS Med. 2016 Nov 22;13(11):e1002175
pubmed: 27875528
Malar J. 2019 Dec 3;18(1):389
pubmed: 31796025
Malar J. 2013 Aug 02;12:272
pubmed: 23914905
Am J Trop Med Hyg. 2015 Oct;93(4):798-800
pubmed: 26283746
Clin Vaccine Immunol. 2008 Aug;15(8):1282-91
pubmed: 18495848
Malar J. 2010 Dec 17;9:363
pubmed: 21167018
J Biol Chem. 2009 Sep 25;284(39):26951-63
pubmed: 19633296
Malar J. 2008 Jul 08;7:123
pubmed: 18611271
Malar J. 2017 Jul 18;16(1):289
pubmed: 28720100
PLoS One. 2018 Mar 5;13(3):e0193296
pubmed: 29505578
Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):778-82
pubmed: 2515634
J Infect Dis. 2016 Jul 15;214(2):329-38
pubmed: 27067196
PLoS One. 2012;7(6):e36996
pubmed: 22675476